首次出版：最新修訂：March 2009交付方式：特快專遞(2-3天送達(dá))
報(bào)告屬性：共123頁(yè)下載目錄 版權(quán)聲明
定購(gòu)電話：0755-82571522、82571566、400-008-1522
24小時(shí)服務(wù)熱線：138 0270 8576 定制報(bào)告
| 版本 | 在線版 | 電子版+印刷版 | 在線報(bào)告庫(kù)（超1000份報(bào)告）全庫(kù) |
|---|---|---|---|
| 優(yōu)惠價(jià) | RMB 6800 | RMB 7800 | RMB 9800 |
| 原價(jià) | RMB 9600 | RMB 9800 | - |
在線報(bào)告庫(kù)有超1000份報(bào)告，
全庫(kù)只需9800元，平均每份報(bào)告僅需9.8元！
聯(lián)系電話： 400 008 0586; 0755-82571568
微信掃碼： 
1.EXECUTIVESUMMARY
·ExecutiveSummary
2.MARKETINTRODUCTION
·ResearchScopeandMethodology
ScopeandSegmentation
ResearchMethodology
·BloodCancerOverview
BloodCancerBiology
BloodCancerDefinitions
·MultipleMyelomaOverview
Etiology
StagingandPrognosticFactors
TreatmentOverview
·PatientForecasts
Prevalence
Incidence
Mortality
Staging
·GeneralMarketTrends
IndustryChallengesandStrategies
MarketDrivers
3.PRODUCTANDPIPELINEANALYSIS
·ApprovedProductAnalysis
ChemotherapyProductAnalysis
SteroidProductAnalysis
InterferonProductAnalysis
ImmunomodulatoryProductAnalysis
·PipelineAnalysis
ChemotherapyPipelineAnalysis
TargetedTherapyLateStagePipelineAnalysis
TargetedTherapyEarlyStagePipelineAnalysis
SupportiveProductPipeline
4.COMPETITIVEANALYSIS
·Introduction
TreatmentTrends
MarketEngineeringMeasurements
CommonDrugRegimens
DrugPrices
·MarketRevenueForecasts
TotalMarketRevenueForecasts
First-lineHSCTEligibleRevenueForecasts
First-lineHSCTNon-EligibleRevenueForecasts
Second-lineRevenueForecasts
Third-line+RevenueForecasts
MarketShareAnalysis
·ProductRevenueForecasts
Alkeran
Doxil
Revlimid
Thalomid
Velcade
Tanespimycin
ZIO-101
Perifosine
5.APPENDIX
·DecisionSupportDatabases
Physicians
GovernmentHealthcareExpenditure
PrivateHealthcareExpenditure
PharmaceuticalR&DExpenditure
PercentPharmaceuticalR&DExpenditure
The U.S. Multiple Myeloma Market is a rapidly progressing field that is set to generate over $3 billion in revenue in the coming years. The market has witnessed unprecedented growth with the launch of three new drugs. The dynamics of this market are changing rapidly and the forecast through 2013 highlights the major changes. This study includes patient forecasts, pipeline analysis and individual product revenue forecasts.
外商投資企業(yè)協(xié)會(huì)會(huì)員單位
最具品牌價(jià)值行業(yè)門戶
發(fā)改委十佳創(chuàng)新案例金典獎(jiǎng)
電子行業(yè)協(xié)會(huì)副會(huì)長(zhǎng)單位
哈爾濱最佳項(xiàng)目策劃智庫(kù)單位
深圳市商業(yè)聯(lián)合會(huì)會(huì)員單位
珠海招商合伙人
重慶市產(chǎn)業(yè)招商聯(lián)盟單位
中投顧問(wèn)協(xié)辦的濟(jì)陽(yáng)區(qū)（深圳） "新能源汽車產(chǎn)業(yè)"專題推介會(huì)
中投顧問(wèn)受邀為合肥市投促部門作機(jī)器人產(chǎn)業(yè)招商培訓(xùn)
中投顧問(wèn)為珠海全市招商系統(tǒng)培訓(xùn)產(chǎn)業(yè)招商大腦獲得圓滿成功
中投顧問(wèn)為漢中市作"大數(shù)據(jù)招商、精準(zhǔn)招商"培訓(xùn)
中投顧問(wèn)項(xiàng)目組赴安慶迎江經(jīng)開區(qū)調(diào)研
湖州市吳興區(qū)駐深辦來(lái)訪中投顧問(wèn)
河北邢臺(tái)南宮市駐深領(lǐng)導(dǎo)赴中投顧問(wèn)拜訪
中投顧問(wèn)陪同廣州某經(jīng)開區(qū)領(lǐng)導(dǎo)赴外商協(xié)會(huì)治談合作
